Results 31 to 40 of about 924 (199)
Case commentary: Uncertainty in evaluating treatment outcomes in carbapenem-resistant acinetobacter baumannii infections [PDF]
, 2021 Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are challenging to treat and associated with poor clinical outcomes. In this issue, sulbactamdurlobactam, a novel b-lactam-b-lactamase inhibitor, was used with cefiderocol to successfully ...
Howard-Anderson J., van Duin D.
core +2 more sources
Biochemical exploration of β-lactamase inhibitors [PDF]
, 2023 The alarming rise of microbial resistance to antibiotics has severely limited the efficacy of current treatment options. The prevalence of β-lactamase enzymes is a significant contributor to the emergence of antibiotic resistance.
Debasish Kar, Varshaa Arer
core +1 more source
A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant [PDF]
, 2021 An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Adams, Mark D +13 more
core +2 more sources
Turning the Tide Against Carbapenem-resistant <i>Acinetobacter baumannii</i>: Advancing Care With Sulbactam-Durlobactam. [PDF]
Open Forum Infect DisSatlin M +3 more
europepmc +3 more sources
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
Antibiotics, 2021 The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci +3 more
doaj +1 more source
mBio, 2022 Mycobacterium abscessus (Mab) infections are a growing menace to the health of many patients, especially those suffering from structural lung disease and cystic fibrosis.
Khalid M. Dousa +15 more
doaj +1 more source
Carbapenemase Inhibitors: Updates on Developments in 2021 [PDF]
, 2022 Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently ...
Allam, Sabine +7 more
core +1 more source
Antimicrobial resistance conferred by OXA-48 β-lactamases:towards a detailed mechanistic understanding [PDF]
, 2021 OXA-48-type β-lactamases are now routinely encountered in bacterial infections caused by carbapenem-resistant Enterobacterales. These enzymes are of high and growing clinical significance due to the importance of carbapenems in treatment of health care ...
Hirvonen, Viivi H A +2 more
core +2 more sources
Antibiotics, 2022 In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories.
Bernardetta Segatore +17 more
doaj +1 more source
Antimicrobial Agents and Chemotherapy, 2023 ABSTRACTAcinetobacter baumannii-calcoaceticuscomplex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused byAcinetobacter, including multidrug- and carbapenem ...
Samir H. Moussa +7 more
openaire +2 more sources